[
  {
    "title": "Henrietta Lacks’ estate settles with Novartis over the ‘stolen cells’ that advanced science",
    "link": "https://www.statnews.com/2026/02/28/henrietta-lacks-novartis-settlement-over-hela-cell-line/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-28T13:49:04.000Z",
    "summary": "Novartis becomes the second company to settle after being accused of reaping rewards from a racist medical system."
  },
  {
    "title": "Kennedy announces new vaccine advisory committee members after meeting rescheduled",
    "link": "https://www.statnews.com/2026/02/27/two-new-members-added-cdc-vaccine-advisory-committee-acip/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-28T01:53:28.000Z",
    "summary": "Kennedy adds two new members to the CDC's vaccine advisory committee"
  },
  {
    "title": "STAT+: Minnesota report shows large hospitals continue to dominate the 340B drug discount program",
    "link": "https://www.statnews.com/pharmalot/2026/02/27/pharma-medicines-hospitals-340b-minnesota-report/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T21:53:28.000Z",
    "summary": "Minnesota hospitals and clinics participating in a controversial U.S. drug discount program reaped at least $1.34 billion in revenue in 2024."
  },
  {
    "title": "STAT+: Trump most-favored nation drug pricing deals end after three years for some companies",
    "link": "https://www.statnews.com/2026/02/27/trump-drug-prices-pharma-mfn-deals-3-year-terms/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T20:58:14.000Z",
    "summary": "SEC filings show that, at least for some drugmakers, \"most-favored nation\" drug pricing deals with President Trump last three years."
  },
  {
    "title": "Kansas’ new ID law could have health consequences for trans people",
    "link": "https://www.statnews.com/2026/02/27/kansas-id-law-impact-health-trans-people-morning-rounds/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T18:54:32.000Z",
    "summary": "Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Happy Friday. If I ever have kids, I want them to be…"
  },
  {
    "title": "Atrium spins out of Avidity, aiming to target rare heart diseases with RNA",
    "link": "https://www.biopharmadive.com/news/atrium-avidity-spinout-novartis-rna-cardiomyopathy-heart/813365/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-27T17:58:42.000Z",
    "summary": "Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease."
  },
  {
    "title": "UniQure falls further on Makary comments",
    "link": "https://www.biopharmadive.com/news/uniqure-makary-cnbc-gene-therapy-rare-disease-stock/813371/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-27T17:08:00.000Z",
    "summary": "Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure's gene therapy for Huntington's won't get approved."
  },
  {
    "title": "Moderna’s combination flu, COVID shot wins over European drug regulators",
    "link": "https://www.biopharmadive.com/news/moderna-europe-covid-flu-vaccine-recommendation-mcombriax/813354/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-27T16:45:00.000Z",
    "summary": "In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S."
  },
  {
    "title": "STAT+: Up and down the ladder: The latest comings and goings",
    "link": "https://www.statnews.com/pharmalot/2026/02/27/pharma-biotech-jobs-merck-roche-kymera/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T16:22:01.000Z",
    "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry."
  },
  {
    "title": "Opinion: Former surgeon general: The Senate must not approve someone who can’t practice medicine as the nation’s top doctor",
    "link": "https://www.statnews.com/2026/02/27/casey-means-surgeon-general-jerome-adams/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T15:17:39.000Z",
    "summary": "“The surgeon general is not a wellness influencer,” writes former Surgeon General Jerome Adams of Casey Means."
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/27/fda-bonus-cigna-pharmacy-abbvie-novartis/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T14:30:55.000Z",
    "summary": "FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and top agency official Vinay Prasad"
  },
  {
    "title": "From ALS to dental floss: Here are the teams competing in STAT Madness 2026",
    "link": "https://www.statnews.com/2026/02/27/stat-madness-2026-contestants-64-teams-from-50-labs/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T09:30:00.000Z",
    "summary": "A genetic test to diagnose ALS. Dental floss that can track your cortisol levels. Check out the 64 innovations and discoveries in our annual STAT Madness bracket."
  },
  {
    "title": "Can an RFK Jr. action figure help cement the MAHA-MAGA alliance?",
    "link": "https://www.statnews.com/2026/02/27/rfk-jr-action-figure-video-hhs-policy-memes/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T09:30:00.000Z",
    "summary": "He’s an action figure. He’s a milk-drinking rave-goer. He’s America’s health secretary."
  },
  {
    "title": "Opinion: I’m a rare disease mom, and I finally have new hope for my son’s future",
    "link": "https://www.statnews.com/2026/02/27/rare-diseases-plausible-mechanism-pathway-fda/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T09:30:00.000Z",
    "summary": "For too long, the promise of personalized therapies has been tantalizingly close, yet frustratingly out of reach for rare-disease families."
  },
  {
    "title": "Opinion: U.S. government must invest more in research around men’s sexual and reproductive health",
    "link": "https://www.statnews.com/2026/02/27/mens-sexual-reproductive-health-contraception-stis-research/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-27T09:30:00.000Z",
    "summary": "It’s high time to focus on sexual and reproductive health for men."
  },
  {
    "title": "Generate caps a strong month for biotech IPOs with $400M offering",
    "link": "https://www.biopharmadive.com/news/generate-biomedicines-ipo-price-biotech-ai-flagship-startup/813130/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-27T01:42:00.000Z",
    "summary": "The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years."
  },
  {
    "title": "STAT+: Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program",
    "link": "https://www.statnews.com/pharmalot/2026/02/26/justice-department-backs-abbvie-340b-hospitals-medicines-pharma/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T21:41:02.000Z",
    "summary": "DOJ is backing AbbVie in its battle to overturn a Colorado law that prohibits pharmaceutical companies from placing restrictions on the 340B drug discount program."
  },
  {
    "title": "STAT+: Cigna, extending reach into prescription drugs, acquires major pharmacy used by hospitals",
    "link": "https://www.statnews.com/2026/02/26/cigna-carepathrx-acquisition-vertical-integration/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T20:24:14.000Z",
    "summary": "Scoop: Cigna has acquired CarepathRx, a large pharmacy backed by private equity that dispenses prescription drugs to nearly 10% of U.S. hospitals."
  },
  {
    "title": "Listen: FDA turmoil, election intrigue, AI, and more",
    "link": "https://www.statnews.com/2026/02/26/listen-fda-turmoil-election-intrigue-ai-readout-loud/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T18:56:06.000Z",
    "summary": "On this week's Readout LOUD: Adam is joined by guest host Jared Holz to talk M&A, FDA turmoil, election intrigue, and more."
  },
  {
    "title": "CMS announces pause on new durable medical equipment suppliers",
    "link": "https://www.statnews.com/2026/02/26/cms-national-moratorium-durable-medical-equipment/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T18:09:50.000Z",
    "summary": "The Trump administration issued a nationwide moratorium on new suppliers for certain medical equipment, citing fraud."
  },
  {
    "title": "Everything you need to know about RFK Jr., MAHA, and ‘glypho-gate’",
    "link": "https://www.statnews.com/2026/02/26/glyphosate-herbicide-maha-backlash-alex-hogan-status-report/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T17:59:03.000Z",
    "summary": "This week on STATus Report, everything you need to know about RFK Jr., MAHA, and \"glypho-gate.\""
  },
  {
    "title": "FDA Grants Second Approval under the National Priority Voucher Pilot Program",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-grants-second-approval-under-national-priority-voucher-pilot-program",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-26T17:38:38.000Z",
    "summary": "The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program."
  },
  {
    "title": "Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial",
    "link": "https://www.biopharmadive.com/news/lilly-orforglipron-rybelsus-diabetes-study-results-glp-1/813209/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T17:10:00.000Z",
    "summary": "Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates."
  },
  {
    "title": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
    "link": "https://www.biopharmadive.com/news/bristol-myers-systimmune-adc-breast-cancer-results-china/813206/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T16:29:55.000Z",
    "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth."
  },
  {
    "title": "STAT+: The nation’s MAHA mom lands in Congress, with some uncomfortable questions",
    "link": "https://www.statnews.com/2026/02/26/dc-diagnosis-the-nations-maha-mom-casey-means/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T16:23:45.000Z",
    "summary": "Casey Means' confirmation hearing, prior auth reforms are a priority, and other updates from D.C. Diagnosis"
  },
  {
    "title": "STAT+: What stands between brain implants and FDA approval?",
    "link": "https://www.statnews.com/2026/02/26/brain-computer-interface-fda-approval-challenges-health-tech/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T16:11:47.000Z",
    "summary": "In this edition of STAT Health Tech: The regulatory challenges faced by startups developing implanted brain-computer interfaces, and more."
  },
  {
    "title": "STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad",
    "link": "https://www.statnews.com/2026/02/26/makary-fda-rare-disease-vinay-prasad-cnbc/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-26T15:20:07.000Z",
    "summary": "FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay Prasad, in an interview with CNBC."
  },
  {
    "title": "Boehringer drug approved in 44 days; BioMarin shelves Roctavian",
    "link": "https://www.biopharmadive.com/news/hernexeos-fda-voucher-roctavian-withdrawal-pfizer-asahi-aicuris/813207/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T14:39:00.000Z",
    "summary": "Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid…"
  },
  {
    "title": "Sarepta CEO Doug Ingram to retire, with company at a crossroads",
    "link": "https://www.biopharmadive.com/news/sarepta-doug-ingram-ceo-retire-duchenne/813169/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-26T13:00:00.000Z",
    "summary": "Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business."
  },
  {
    "title": "The therapeutic potential of orphan adhesion G-protein-coupled receptors",
    "link": "https://www.nature.com/articles/s41573-025-01371-6",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-26T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Dose-finding and optimization in drug development for rare diseases",
    "link": "https://www.nature.com/articles/d41573-026-00035-3",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-26T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "Trump’s State of the Union trumpets healthcare greatest hits, but no new policies",
    "link": "https://www.biopharmadive.com/news/trump-state-of-the-union-healthcare-2026/813159/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T22:16:00.000Z",
    "summary": "In his lengthy address Tuesday night, the president touted his efforts to make drugs and insurance more affordable but steered clear of hot-button issues like vaccine access and the GOP’s Medicaid…"
  },
  {
    "title": "Alkermes’ Richard Pops to step down after three-decade run as CEO",
    "link": "https://www.biopharmadive.com/news/alkermes-richard-pops-ceo-succession-blair-jackson/813073/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-25T16:54:00.000Z",
    "summary": "One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug."
  },
  {
    "title": "Gilead pays US$7.8 billion for Arcellx’s next-generation CAR T candidate",
    "link": "https://www.nature.com/articles/d41573-026-00034-4",
    "source": "Nature Reviews Drug Discovery",
    "category": "research",
    "date": "2026-02-25T00:00:00.000Z",
    "summary": ""
  },
  {
    "title": "FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-23T16:32:48.000Z",
    "summary": "The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety…"
  }
]
